[go: up one dir, main page]

DE60315827D1 - Verbesserte polysaccharid- und glykokonjugat-vakzine - Google Patents

Verbesserte polysaccharid- und glykokonjugat-vakzine

Info

Publication number
DE60315827D1
DE60315827D1 DE60315827T DE60315827T DE60315827D1 DE 60315827 D1 DE60315827 D1 DE 60315827D1 DE 60315827 T DE60315827 T DE 60315827T DE 60315827 T DE60315827 T DE 60315827T DE 60315827 D1 DE60315827 D1 DE 60315827D1
Authority
DE
Germany
Prior art keywords
glycoconjugate vaccine
polysaccharide
improved polysaccharide
improved
polyfunctional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60315827T
Other languages
English (en)
Other versions
DE60315827T2 (de
DE60315827T3 (de
Inventor
Massimo Porro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosynth SRL
Original Assignee
Biosynth SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29415984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60315827(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biosynth SRL filed Critical Biosynth SRL
Publication of DE60315827D1 publication Critical patent/DE60315827D1/de
Publication of DE60315827T2 publication Critical patent/DE60315827T2/de
Application granted granted Critical
Publication of DE60315827T3 publication Critical patent/DE60315827T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Sustainable Development (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
DE60315827T 2002-05-09 2003-05-07 Verbesserte polysaccharid- und glykokonjugat-vakzine Expired - Lifetime DE60315827T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
WOPCT/IT02/00307 2002-05-09
PCT/IT2002/000307 WO2003094961A1 (en) 2002-05-09 2002-05-09 Improved polysaccharide and glycoconjugate vaccines_____________
PCT/EP2003/004948 WO2003094959A1 (en) 2002-05-09 2003-05-07 Improved polysaccharide and glycoconjugate vaccines
EP03749887A EP1501542B2 (de) 2002-05-09 2003-05-07 Verbesserte polysaccharid- und glykokonjugat-vakzine

Publications (3)

Publication Number Publication Date
DE60315827D1 true DE60315827D1 (de) 2007-10-04
DE60315827T2 DE60315827T2 (de) 2008-05-15
DE60315827T3 DE60315827T3 (de) 2012-04-26

Family

ID=29415984

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60315827T Expired - Lifetime DE60315827T3 (de) 2002-05-09 2003-05-07 Verbesserte polysaccharid- und glykokonjugat-vakzine

Country Status (8)

Country Link
US (1) US7588765B2 (de)
EP (1) EP1501542B2 (de)
AT (1) ATE370745T1 (de)
AU (2) AU2002309259A1 (de)
CA (1) CA2484279A1 (de)
DE (1) DE60315827T3 (de)
ES (1) ES2293002T5 (de)
WO (2) WO2003094961A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020293A1 (en) * 2003-06-23 2007-01-25 Michon Francis J Vaccines against group neisseria meningitidis and meningococcal combinations thereof
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
RS52249B (en) 2005-04-08 2012-10-31 Wyeth Llc MULTIVALENT COMPOSITION WITH CONJUGATE OF PNEUMOCOCOCH POLISACCHARIDE AND PROTEIN
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
US20110159130A1 (en) * 2007-02-28 2011-06-30 Sanjay Jain Reduction of endotoxin in polysialic acids
GB0810894D0 (en) * 2008-06-13 2008-07-23 Novartis Vaccines & Diagnostic Conjugated saccharide
EP2411039A4 (de) 2009-03-23 2015-05-06 Brigham & Womens Hospital Glycokonjugat-impfstoffe
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
WO2011148382A1 (en) 2010-05-28 2011-12-01 Biological E Limited An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
ITMI20130142A1 (it) * 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
EA035556B1 (ru) * 2014-07-25 2020-07-07 Биосинз С.Р.Л. Гликоконъюгатные вакцины, содержащие основные структурные единицы молекулярной конструкции, экспрессирующей встроенные множественные эпитопы, для составления вакцины широкого спектра действия против инфекций, вызываемых энтеропатогенными бактериями
US10307474B2 (en) 2014-08-08 2019-06-04 Glaxosmithkline Biologicals S.A. Modified host cells and hybrid oligosaccharides for use in bioconjugate production
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
BR112019003992A2 (pt) 2016-09-02 2019-05-28 Sanofi Pasteur Inc vacina contra neisseria meningitidis
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3691677A4 (de) 2017-10-04 2021-07-07 Pogona, Llc Saccharid-polypeptidkonjugat-zusammensetzungen und verfahren zur verwendung davon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663160A (en) * 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5371186A (en) * 1991-02-11 1994-12-06 Biosynth S.R.L. Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
AU678549B2 (en) 1992-01-16 1997-06-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Detoxified LPS-cholera toxin conjugate vaccine for prevention of cholera
IT1287158B1 (it) * 1996-11-13 1998-08-04 Biosynth Srl Uso combinato di peptidi sintetici anti-endotossina e di anticorpi anti-endotossina per la profilassi ed il trattamento delle
US6951652B2 (en) * 1998-07-29 2005-10-04 Biosynth S.R.L. Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases

Also Published As

Publication number Publication date
EP1501542B1 (de) 2007-08-22
WO2003094959A1 (en) 2003-11-20
ES2293002T3 (es) 2008-03-16
EP1501542B2 (de) 2011-11-02
US7588765B2 (en) 2009-09-15
ES2293002T5 (es) 2012-03-20
AU2002309259A1 (en) 2003-11-11
DE60315827T2 (de) 2008-05-15
ATE370745T1 (de) 2007-09-15
WO2003094961A1 (en) 2003-11-20
US20060165730A1 (en) 2006-07-27
AU2003242535A1 (en) 2003-11-11
CA2484279A1 (en) 2003-11-20
DE60315827T3 (de) 2012-04-26
EP1501542A1 (de) 2005-02-02

Similar Documents

Publication Publication Date Title
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
MY125202A (en) Vaccine
MXPA05014016A (es) Proteinas portadoras para vacunas.
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
DK1699822T3 (da) IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
CY1113243T1 (el) Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4
DE60141773D1 (de) Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
DK1309692T3 (da) Anti-IL12-antistoffer, præparater, fremgangsmåder og anvendelser
BR122018016045B8 (pt) proteína variante otimizada
WO2004063963A3 (en) Novel proteins with altered immunogenicity
NO20063254L (no) Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
NO20083127L (no) Fremgangsmater og preparater for malretting av polyubiquitin
CR8231A (es) Anticuerpos rg1 y uso de los mismos
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DE60037900D1 (de) Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
CY1108526T1 (el) Εμβολια εναντι καρκινων
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
DE60238555D1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
ATE406449T1 (de) Antigene und vektoren für impfung
DE60025704D1 (de) Das goodpasture-antigen bindende protein
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164

Legal Events

Date Code Title Description
8363 Opposition against the patent
R102 Epo decision maintaining patent in amended form now final

Ref document number: 1501542

Country of ref document: EP

R102 Epo decision maintaining patent in amended form now final

Ref document number: 1501542

Country of ref document: EP

Effective date: 20111102